# US 2023/0181604 A1 · Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0181604 A1
- Document ID: US20230181604A1
- Status: Published application
- Kind: A1
- Application number: 17/916,702
- Filed: 2021-04-05
- Published: 2023-06-15
- Earliest claimed: 2020-04-03
- Assignees: Mitotech SA
- Applicants: Mitotech S.A.
- Inventors: Maxim V. SKULACHEV; Roman ZINOVKIN; Alexander ANDREEV-ANDRIEVSKY; Maxim EGOROV; Elena KARGER; Anton PETROV; Lawrence FRIEDHOFF
- Web page: https://patentgrep.com/patent/US20230181604A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/66: Phosphorus compounds
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Mitochondrially targeted antioxidants are used to prevent and treat severe inflammatory conditions including viral infection (such as COVID-19), systemic shock, trauma, burns, surgery associated with significant tissue damage, toxic damage, and damage associated with autoimmune reactions.

## Claims

### Claim 1

A method to aid in treating or preventing an inflammatory condition in a subject in need thereof, the method comprising administration of a mitochondrially-targeted antioxidant of formula I (SkQ)
wherein A is an effector moiety/antioxidant optionally having the following structure:
and/or a reduced form thereof, wherein m is an integer from 1 to 3; each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
wherein L is a linker group, comprising:
a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; and/or
b) a natural isoprene chain;
wherein n is integer from 1 to 40;
wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
and/or solvates, salts, isomers, or prodrugs thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein SkQ is compound SkQ1 shown below, in its reduced or oxidized form:
or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein SkQ is a compound selected from the group consisting of the following compounds:

### Claim 4

The method of any of the preceding claims, wherein the inflammatory condition is associated with infection, COVID-19, sepsis or septic shock, cytokine storm or SIRS, vascular endothelial damage, activation of vascular endothelial cells, PAMPS, DAMPS, cold shock, heat shock, toxic shock, burn trauma, surgery, autoimmune disease, anaphylaxis, cancer, ischemic disease, or presence of CIRP and/or HMGB1 in the blood of the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the infection is bacterial infection, fungal infection, or viral infection.

### Claim 6 (depends on 5)

The method of claim 5, wherein the viral infection is infection by an influenza virus or a corona virus, such as SARS-CoV-2.

### Claim 7

The method of any of the preceding claims, wherein SkQ is administered by intravenous injection or infusion, subcutaneous injection, or a slow release formulation or device.

### Claim 8

The method of any of the preceding claims, wherein the method prevents deconstruction of cell-to-cell contacts between endothelial cells of the subject.

### Claim 9

The method of any of the preceding claims, further comprising administering an additional therapeutic agent.

### Claim 10

The method of any of the preceding claims, wherein the method prevents the subject from contracting COVID-19.

### Claim 11

A kit comprising mitochondrially-targeted antioxidant SkQ of formula I below and instructions for performing the method of any of the preceding claims:
wherein A is an effector moiety/antioxidant optionally having the following structure:
and/or a reduced form thereof, wherein m is an integer from 1 to 3; each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
wherein L is a linker group, comprising:
a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; and/or
b) a natural isoprene chain;
wherein n is integer from 1 to 40;
wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
and/or solvates, salts, isomers, or prodrugs thereof.

### Claim 12

A composition for use in treating or preventing an inflammatory condition in a subject in need thereof, the composition comprising a mitochondrially-targeted antioxidant of formula I (SkQ)
wherein A is an effector moiety/antioxidant optionally having the following structure:
and/or a reduced form thereof, wherein m is an integer from 1 to 3; each Y is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, or two adjacent Y groups, together with carbon atoms to which they are attached, forming the following structure:
and/or a reduced form thereof, wherein R1 and R2 may be the same or different and are each independently C1-6 alkyl or C1-6 alkoxy;
wherein L is a linker group, comprising:
a) straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; and/or
b) a natural isoprene chain;
wherein n is integer from 1 to 40;
wherein B is a mitochondria-targeting group comprising a lipophilic cation and a pharmacologically acceptable anion;
and/or solvates, salts, isomers, or prodrugs thereof.

### Claim 13 (depends on 12)

The composition of claim 12 wherein SkQ is compound SkQ1 shown below, in its reduced or oxidized form:
or a combination thereof.

### Claim 14 (depends on 12)

The composition of claim 12, wherein SkQ is a compound selected from the group consisting of the following compounds:

### Claim 15 (depends on 12, 13, 14)

The composition of any of claims 12-14, wherein the inflammatory condition is associated with infection, COVID-19, sepsis or septic shock, cytokine storm or SIRS, vascular endothelial damage, activation of vascular endothelial cells, PAMPS, DAMPS, cold shock, heat shock, toxic shock, burn trauma, surgery, autoimmune disease, anaphylaxis, cancer, ischemic disease, or presence of CIRP and/or HMGB1 in the blood of the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the infection is bacterial infection, fungal infection, or viral infection.

### Claim 17 (depends on 16)

The method of claim 16, wherein the viral infection is infection by an influenza virus or a corona virus, such as SARS-CoV-2.
